Fresa Alberto, Innocenti Idanna, Tomasso Annamaria, Stirparo Luca, Mosca Antonio, Iadevaia Francesco, Autore Francesco, Laurenti Luca
Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Ther Adv Hematol. 2024 Nov 11;15:20406207241282570. doi: 10.1177/20406207241282570. eCollection 2024.
The incidence of pure red cell aplasia (PRCA) in chronic lymphocytic leukemia (CLL) is <1% and treatments include the use of steroids and therapeutic strategies including immunosuppressive therapies. Here we present a case of a CLL-associated PRCA successfully treated with acalabrutinib, a treatment never described before for this specific condition, obtaining a rapid response after failing two lines of therapy. Exploring the treatment rationale, both the immune modulation and the continuous control of the disease, could have played a role in the treatment efficacy. Covalent BTK inhibitors are an effective treatment option for autoimmune complications of CLL, including CLL-associated PRCA.
慢性淋巴细胞白血病（CLL）中纯红细胞再生障碍性贫血（PRCA）的发生率<1%，治疗方法包括使用类固醇以及免疫抑制疗法等治疗策略。本文报告1例CLL相关的PRCA患者，该患者在两线治疗失败后，使用阿卡替尼成功治疗，这是此前从未有过针对此特定情况的治疗报道，用药后获得了快速缓解。探究治疗原理，免疫调节和疾病的持续控制可能都对治疗效果起到了作用。共价BTK抑制剂是治疗CLL自身免疫并发症（包括CLL相关的PRCA）的有效治疗选择。
